Rapport Therapeutics Chief Development Officer Krishnaswamy Yeleswaram disposes of 404 common shares worth $20,159.6
RAPP•Insider share sale
- Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy sold 404 common shares on Aug. 19, 2026 at USD 49.9.
- Direct holdings fell to 246,022 shares following the transaction.
